North America led the global pancreatic elastase testing market with a 29.7% revenue share, driven by advanced healthcare infrastructure and disease prevalence.
NEWARK, DEL: The pancreatic elastase testing market was estimated at US$ 15.5 Million in 2022; by 2033, it is anticipated to grow to US$ 36.2 Million. With a value share of around 58.4%, ELISA kits led the global market for this product category in 2022. From 2023 to 2033, they are projected to increase at a CAGR of nearly 7.9%.
The pancreatic elastase testing market is poised for substantial growth, driven by the rising demand for non-invasive diagnostic tools and significant technological advancements. As healthcare trends shift towards minimally invasive methods, the demand for accurate and convenient diagnostic options is rising. Pancreatic elastase testing offers a non-invasive approach to assess pancreatic function, making it an attractive option for patients and healthcare providers.
Request to Download Sample PDF Summary! https://www.futuremarketinsights.com/reports/sample/rep-gb-14047
Technological advancements have further propelled the market forward. The development of advanced elastase testing methods, such as immunoassays and point-of-care testing devices, has significantly improved the accuracy and speed of results. These innovations enhance diagnostic capabilities and improve patient outcomes by enabling early detection and effective management of pancreatic disorders.
The market’s growth potential is underscored by its relevance in addressing various gastrointestinal disorders, including pancreatitis, cystic fibrosis, and malabsorption syndromes. Additionally, the aging global population and the prevalence of pancreatic-related ailments increase the demand for efficient and accurate diagnostic tools.
In conclusion, the pancreatic elastase testing market is set to expand due to the growing preference for non-invasive diagnostics and continuous technological advancements. These factors offer healthcare professionals and patients improved diagnostic capabilities and better disease management options, positioning the market for significant growth in the coming years.
Key Takeaways from the Market Study:
- By product, ELISA kits accounted for a significant share of the global pancreatic elastase testing market, with a valuation of USD 9.0 Million in 2022. ELISA kits enable accurate pancreatitis diagnosis through precise quantification of pancreatic elastase levels, aiding early detection and effective management.
- With a valuation of USD 5.4 Million in 2022, the chronic pancreatitis indication accounted for a significant portion of the global pancreatic elastase testing market. Chronic pancreatitis’ prevalence, impact on patient’s lives, and its link to risk factors like alcohol consumption drive the demand for accurate diagnostic tools like pancreatic elastase testing, making it a pivotal indication in the Pancreatic Elastase Market.
- In 2022, the fecal sample held substantial value at USD 14.4 Million, contributing significantly to the global pancreatic elastase testing market. Fecal elastase-1 testing via ELISA is a practical and reliable method for diagnosing exocrine pancreatic insufficiency due to its stability and high sensitivity.
- Hospitals held the prominent end-user market share in the global pancreatic elastase testing market in 2022, growing rapidly with a CAGR of 9.3% in the predicted period. Hospitals are essential for the pancreatic elastase testing market, serving as primary diagnostic centers for accurate pancreatic disease detection and treatment planning.
- North America maintained the predominant regional position in the global pancreatic elastase testing market in 2022, with a revenue share of 29.7%. North America dominates the global pancreatic elastase testing market due to advanced healthcare infrastructure, high disease prevalence, and a supportive regulatory environment.
Embrace Elevated Awareness as our Enlightening Methodology Insights Guide You: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14047
Market Competition Analysis
Key competitors like CerTest BIOTEC S.L. Laboratories and Seikagaku compete fiercely in the pancreatic elastase testing industry. These businesses frequently participate in conferences, compete in product awards, and release new goods to capture a greater market share, emphasizing accessibility, practicality, and efficiency.
- In June 2023, CerTest BIOTEC S.L. Laboratories will verify the Pancreatic Elastase Turbilatex test for use with automatic analyzers-optimized quantitative identification of Pancreatic Elastase E1 in stool samples.
- In July 2021, DiaSorin has acquired Luminex Corporation, acquiring its multiplexing technology and portfolio, which will enhance its existing offerings and expand its US presence.
Other Companies Profiled:
- ALPCO Diagnostics
- ScheBo Biotech AG
- Immundiagnostik AG
- Invivo Healthcare
- DRG Instruments GMBH
- Verisana Laboratories
- BÜHLMANN Laboratories AG
- R-Biopharm AG
- American Laboratory Products Company, Ltd.
- Vitassay Healthcare, S.L.U.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the pancreatic elastase testing market in its latest study, presenting a historical demand assessment of 2017 to 2022 and projections for 2023 to 2033. The global pancreatic elastase testing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader
The research study is based on product (ELISA kits, turbidimetric kits, CLIA kits, and rapid test kits), indication (chronic pancreatitis, type 1 diabetes, cystic fibrosis, and others), by sample (fecal and blood), and end-user (hospitals, diagnostic laboratories, and specialty clinics), across seven key regions of the world.
Segmentation Covered in the Pancreatic Elastase Testing Industry Research:
- ELISA Kits
- Turbidimetric Kits
- CLIA Kits
- Rapid Test Kits
- Chronic Pancreatitis
- Type 1 Diabetes
- Cystic Fibrosis
By End User:
- Diagnostics Laboratories
- Specialty Clinics
- North America
- Latin America
- South Asia
- East Asia
- Middle East and Africa
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI’s related ongoing Coverage in Healthcare Market Insights Domain
Fecal Pancreatic Elastase Testing Market Size: The fecal pancreatic elastase testing market is expected to increase from US$ 15,306.7 million in 2023 to US$ 31,842.3 million by 2033. The market is likely to capture a 7.6% CAGR from 2023 to 2033.
Cell-free Fetal DNA Testing Market Share: The cell-free fetal DNA testing market is to capture a CAGR of 10.9% during the forecast period. The market is projected to be valued at US$ 1,466.3 million in 2023 and is likely to be worth US$ 4,124.7 million by 2033.
Respiratory Pathogen Testing Kits Market Demand: The global respiratory pathogen testing kits market is expected to record a CAGR of 5.7% from 2023 to 2033. In 2023, the market size is projected to reach a valuation of US$ 4,083.1 million. By 2033, the valuation is expected to be worth US$ 7,136.8 million.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
For Sales Enquiries: [email protected]
LinkedIn| Twitter| Blogs | YouTube